Peptide library

What is the
SNAP-8 peptide?

SNAP-8 is sold as a cosmetic ingredient. What the molecule is, how it relates to argireline, who produced the evidence behind it, and how US, UK and Australian cosmetics law treats it in November 2026.

Short answerCompound research · 8 min read · Updated 18 Nov 2026

SNAP-8 is the trade name of acetyl octapeptide-3, a synthetic eight-amino-acid peptide used in cosmetics. It is argireline’s six-amino-acid sequence with alanine and aspartic acid added, described as mimicking part of SNAP-25, a protein nerve cells use to release signals. The lab figures reviews quote come from its manufacturer, and the peer-reviewed human studies we found tested it only inside multi-ingredient patches.

Key takeaways

  • SNAP-8 is a trade name. FDA’s substance registry records its cosmetic ingredient (INCI) name as acetyl octapeptide-3; its sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2.
  • It is argireline (acetyl hexapeptide-8, also listed as acetyl hexapeptide-3) with two amino acids, alanine and aspartic acid, added at one end.
  • Reviews describe it as competing with SNAP-25 in the SNARE complex, the protein machinery nerve cells use to release messengers; a 2020 review took its lab figures from the manufacturer’s website.
  • The two peer-reviewed human studies naming it that we found (2020, 2024) tested microneedle patches that combined it with other active ingredients, so they cannot isolate its contribution.
  • In the US, Great Britain and Australia, the product’s claims and intended use decide whether it is a cosmetic; none of the rules we read requires a regulator to check that a cosmetic works before sale.

01SNAP-8 at a glance

The short version, dated 18 November 2026. Every line is sourced at the end of the page.

QuestionSNAP-8
What it isA trade name for acetyl octapeptide-3: a synthetic peptide of eight amino acids, made as a cosmetic ingredient.
SequenceAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, capped by an acetyl group at one end and an amide at the other.
Formula and massC41H70N16O16S; 1075.2 g/mol by PubChem’s calculation (CID 76283482). CAS 868844-74-0.
Cosmetic ingredient (INCI) nameAcetyl octapeptide-3, as FDA’s substance registry records it. Also listed as acetyl octapeptide-1 and acetyl glutamyl heptapeptide-3.
Relation to argirelineArgireline (INCI acetyl hexapeptide-8, also listed as acetyl hexapeptide-3) is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. SNAP-8 is the same chain with alanine and aspartic acid added.
ProducerLipotec, Barcelona, according to a 2025 review.
Evidence tierT4: laboratory assays; the figures reviews quote come from the manufacturer. T2: two small human studies of multi-ingredient patches.
United StatesRegulated by intended use. No FDA approval before sale; a claim to affect the body’s structure or function makes a product a drug.
Great BritainUK Cosmetics Regulation: a responsible person, a safety assessment and notification to OPSS before sale.
AustraliaCosmetic ingredients can be industrial chemicals, regulated under the Industrial Chemicals Act 2019; a product used for a therapeutic purpose is a therapeutic good.
WADANot named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. See peptides and anti-doping.

02What is SNAP-8, and how does it relate to argireline?

SNAP-8 is a trade name. The ingredient’s cosmetic name (its INCI name) is acetyl octapeptide-3, which is how FDA’s Global Substance Registration System records it. It is a synthetic chain of eight amino acids: glutamic acid, glutamic acid, methionine, glutamine, arginine, arginine, alanine and aspartic acid. An acetyl group caps one end and an amide the other. The same registry and PubChem also list it as acetyl octapeptide-1 and acetyl glutamyl heptapeptide-3. A 2025 review names Lipotec, in Barcelona, as its producer.

Argireline’s sequence, plus two. Argireline, INCI name acetyl hexapeptide-8 (also listed as acetyl hexapeptide-3), is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. SNAP-8 keeps those six amino acids and adds alanine and aspartic acid. Argireline’s developers described it in 2002 as the product of “a rational design programme” to find “non-toxic molecules that mimic the action of” botulinum neurotoxins. A 2025 review says it was modelled on one end of SNAP-25, a protein nerve cells use to release chemical messengers. More on this family of ingredients: peptides in skincare.

03How is SNAP-8 meant to work?

Nerve cells signal to muscles by releasing chemical messengers stored in small sacs, called vesicles. A group of proteins, the SNARE complex, which includes SNAP-25, docks those vesicles so the messengers can be released.

Reviews describe SNAP-8 as mimicking one end of SNAP-25 and competing with it for a place in the SNARE complex, so that fewer messengers are released. That is a design idea tested in laboratory assays (T4), not a measured effect in people. A 2020 peer-reviewed review gives figures for SNAP-8 in those assays and for wrinkle measurements, and names their source: “the data available in the manufacturer’s website”. We do not repeat those figures. We found no peer-reviewed publication of them (PubMed and Europe PMC, 18 November 2026).

The delivery question. To work this way, a peptide applied to skin has to reach the nerve endings beneath it. For argireline, a 2025 review concluded that “the ability of AH-8 to reach neuromuscular junctions remains uncertain”. We found no published study that measured whether SNAP-8 reaches nerve endings through skin.

04Where does the evidence on SNAP-8 come from?

Every primary source we found came from the company that makes SNAP-8 or involved companies whose products contain it.

SourceWho produced itWhat it testedWhat it cannot show
Manufacturer data, as cited in a 2020 reviewThe producer, on its website (as the review cites it)Laboratory assays of the SNARE complex and messenger release; wrinkle measurementsMethods, sample sizes and full results are not in the peer-reviewed literature we found
Shin et al., 2024 (Annals of Dermatology)Raphas Co., the patch maker, with the Catholic University of Korea; Raphas supported the study24 adults aged 30 to 65: a microneedle patch with acetyl octapeptide-3 and two other active ingredients by one eye, a placebo patch by the other, for 28 days. Measures: wrinkle roughness, skin water loss, elasticity, eye lift, adverse effectsSNAP-8’s share of any change, since the patch had three active ingredients; anything beyond 28 days
Avcil et al., 2020 (Journal of Cosmetic Dermatology)Imperial Bioscience (UK), Dermatest GmbH (Germany) and Raphas Co. (Korea)A 12-week single-centre study of microneedle patches combining acetyl octapeptide-3 with other peptides, adenosine and seaweed extracts: hydration, wrinkles, skin density and thicknessSNAP-8’s share of any change; the abstract does not give the number of people or say whether there was a control group
Reviews (2020 and 2025)Review authorsNothing new: they summarise other sources, including the manufacturer’sIndependent confirmation of the manufacturer’s figures

We searched PubMed and Europe PMC under each of its names and its sequence. Only the two patch studies name it in their title or abstract (18 November 2026), and both include authors from the patch maker. We found no peer-reviewed trial of SNAP-8 on its own. The authors of the 2024 study reported no adverse effects in 24 people over 28 days; a study that size cannot detect uncommon reactions. How we weigh studies like these: evidence grades.

05How do US, UK and Australian cosmetics laws treat SNAP-8?

All three markets decide by the product, not the molecule: what it claims, what form it takes and what it is for.

MarketWhat makes it a cosmeticBefore saleWhen it is not a cosmetic
United States (FDA)Intended use. The law defines cosmetics as articles applied to the body “for cleansing, beautifying, promoting attractiveness, or altering the appearance”.“Cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market.” Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), facilities register, products are listed and serious adverse events are reported to FDA.A product “intended to affect the structure or any function of the body” is a drug. FDA’s examples of drug claims include promises to “regenerate cells”.
Great Britain (UK Cosmetics Regulation)A substance placed on the external parts of the body mainly to clean, perfume, protect or keep them in good condition, change their appearance or correct body odours (Article 2).A responsible person with a UK address, a safety assessment, and notification to the Office for Product Safety and Standards (OPSS). The responsible person must “be able to prove that any claims made when marketing the product are correct”.“A substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product.” For borderline products, the MHRA applies the medicines tests.
AustraliaThe Industrial Chemicals Act 2019 defines a cosmetic by purposes such as cleansing, perfuming, protecting or changing the appearance of an external part of the body, and excludes therapeutic goods.Cosmetic ingredients can be industrial chemicals, regulated under that Act.The TGA says a peptide product is a therapeutic good if, for example, it is “promoted, supplied or generally used for a therapeutic purpose”, which includes to “influence, inhibit or modify a physiological process in the body”.

Two points matter for SNAP-8. Wrinkle care sits inside cosmetics in the UK: the MHRA’s guidance notes that the Regulation’s recital (7) lists “anti-wrinkle products” among cosmetic products, and that the MHRA “only classifies finished products and not individual substances and ingredients”. And the claim decides the category. A product said to act on nerves or muscles is claiming to change how the body works, the kind of claim FDA and the TGA treat as a medicine’s. None of the rules we read requires a regulator to check, before sale, that a cosmetic works. More: what “research use only” means and the skin research area.

06What we don’t know about SNAP-8

  • Whether SNAP-8 on its own changes skin in people. We found no peer-reviewed trial of it as a single ingredient.
  • Whether it reaches the nerve endings under intact skin. That question is open even for argireline, its shorter parent sequence.
  • How the manufacturer’s studies were run: their size, controls and full results are not in the peer-reviewed literature we found.
  • What longer use looks like. The two published human studies lasted 28 days and 12 weeks.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration, Global Substance Registration System. Acetyl octapeptide-3 (UNII 8K14HJF88S: INCI name, brand name SNAP-8, sequence, other names) and acetyl hexapeptide-8 (UNII L4EL31FWIL: argireline, acetyl hexapeptide-3). Substance records read through the GSRS API, 18 Nov 2026. gsrs.ncats.nih.gov/ginas/app/beta/substances/8K14HJF88S
  2. PubChem. Acetyl octapeptide-3, CID 76283482 (formula, computed molecular weight, synonyms including acetyl octapeptide-1 and acetyl glutamyl heptapeptide-3). Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/76283482
  3. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?) (FD&C Act sections 201(i) and 201(g)(1); approval requirements; drug-claim examples). Web page, content current as of 11 Sep 2024; read 18 Nov 2026. And: Modernization of Cosmetics Regulation Act of 2022 (MoCRA), content current as of 29 Oct 2026; read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  4. Regulation (EC) No 1223/2009 on cosmetic products, as it applies in Great Britain: Articles 2 and 20. legislation.gov.uk, revised text (version from 15 Aug 2026); read 18 Nov 2026. www.legislation.gov.uk/eur/2009/1223/article/2
  5. Office for Product Safety and Standards. Making cosmetic products available to consumers in Great Britain. Guidance, published 4 Oct 2021; read 18 Nov 2026. And: MHRA. Guidance Note 8: a guide to what is a medicinal product, sections on classification and cosmetics. Guidance, published September 2025; read 18 Nov 2026. www.gov.uk/guidance/making-cosmetic-products-available-to-co…
  6. Industrial Chemicals Act 2019 (Cth), section 9, definition of cosmetic. Federal Register of Legislation, Compilation No. 6 (C2024C00495, in force from 14 Oct 2024); read 18 Nov 2026. www.legislation.gov.au/C2019A00012/latest/text
  7. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; tga.gov.au did not respond on 18 Nov 2026, read on the Internet Archive capture of 5 Nov 2026, the newest. www.tga.gov.au/resources/explore-topic/peptide-products
  8. World Anti-Doping Agency. Prohibited List 2026 and Prohibited List 2027 (in force 1 Jan 2027), searched 18 Nov 2026; and 2027 Prohibited List: summary of major modifications and explanatory notes (S0). International Standard and explanatory note; read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  9. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem, 2020;8:572923. PMID 33195061 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC7662462/
  10. Badilli U, Inal O. Current approaches in cosmeceuticals: peptides, biotics and marine biopolymers. Polymers (Basel), 2025;17(6):798. PMID 40292641 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC11946782/
  11. Shin JY, Han D, Yoon KY, Jeong DH, Park YI. [Split-face study of a dissolving microneedle patch containing acetyl octapeptide-3 and two other active ingredients, 24 adults, 28 days.] Ann Dermatol, 2024;36(4):215–224. PMID 39082657 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC11291098/
  12. Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. [Single-centre 12-week study of hyaluronic acid microneedle patches containing several peptides, including acetyl octapeptide-3.] J Cosmet Dermatol, 2020;19(2):328–337. PMID 31134751 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/31134751/
  13. Blanes-Mira C, Clemente J, Jodas G, et al. [Design and laboratory study of the hexapeptide argireline, Ac-EEMQRR-NH2.] Int J Cosmet Sci, 2002;24(5):303–310. PMID 18498523. And: Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl hexapeptide-8 in cosmeceuticals: a review of skin permeability and efficacy. Int J Mol Sci, 2025;26(12):5722. PMID 40565185 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC12193160/
  14. Literature searches run 18 Nov 2026: PubMed (title/abstract) and Europe PMC for “SNAP-8”, “snap 8”, “acetyl octapeptide-3”, “octapeptide-3”, “acetyl octapeptide-1”, “acetyl glutamyl heptapeptide” and “Ac-EEMQRRAD”; two records name it in title or abstract (PMIDs 31134751, 39082657). Database queries. pubmed.ncbi.nlm.nih.gov/?term=%22octapeptide-3%22%5Btiab%5D

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What is SNAP-8 peptide?

SNAP-8 is the trade name of acetyl octapeptide-3, a synthetic peptide of eight amino acids (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) used as a cosmetic ingredient.

What is the INCI name for SNAP-8?

Acetyl octapeptide-3, as FDA’s substance registry records it. It is also listed as acetyl octapeptide-1 and acetyl glutamyl heptapeptide-3.

Is SNAP-8 the same as acetyl hexapeptide-8?

No. Acetyl hexapeptide-8, sold as argireline, has six amino acids. SNAP-8 has the same six plus alanine and aspartic acid, so it is a longer, different molecule.

Has SNAP-8 been tested in people?

Only inside multi-ingredient products, in the peer-reviewed studies we found: two small microneedle-patch studies, published in 2020 and 2024, both involving the patch maker. We found no peer-reviewed trial of SNAP-8 on its own (PubMed and Europe PMC, 18 November 2026).

Is SNAP-8 a drug or a cosmetic?

That depends on the product, not the molecule. In the US, Great Britain and Australia, a product limited to cosmetic purposes and claims is regulated as a cosmetic; one claimed to change how the body works can be regulated as a medicine.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page